0001140361-23-010771.txt : 20230308
0001140361-23-010771.hdr.sgml : 20230308
20230308213043
ACCESSION NUMBER: 0001140361-23-010771
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230306
FILED AS OF DATE: 20230308
DATE AS OF CHANGE: 20230308
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: ELMS STEVE
CENTRAL INDEX KEY: 0001250195
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36728
FILM NUMBER: 23717986
MAIL ADDRESS:
STREET 1: 888 SEVENTH AVE
STREET 2: 29TH FL
CITY: NEW YORK
STATE: NY
ZIP: 10106
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ADMA BIOLOGICS, INC.
CENTRAL INDEX KEY: 0001368514
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 562590442
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: C/O ADMA BIOLOGICS, INC.
STREET 2: 465 STATE ROUTE 17
CITY: RAMSEY
STATE: NJ
ZIP: 07446
BUSINESS PHONE: (201) 478-5552
MAIL ADDRESS:
STREET 1: C/O ADMA BIOLOGICS, INC.
STREET 2: 465 STATE ROUTE 17
CITY: RAMSEY
STATE: NJ
ZIP: 07446
FORMER COMPANY:
FORMER CONFORMED NAME: R&R ACQUISITION VI, INC
DATE OF NAME CHANGE: 20060707
4
1
form4.xml
X0306
4
2023-03-06
0001368514
ADMA BIOLOGICS, INC.
ADMA
0001250195
ELMS STEVE
888 SEVENTH AVE
12TH FLOOR
NEW YORK
NY
10106
true
Common Stock
2023-03-06
4
A
0
25815
0
A
52401
D
Common Stock
3615671
I
See Footnote
Employee Stock Option (right to buy)
3.35
2023-03-06
4
A
0
51630
0
A
2033-03-06
Common Stock
51630
51630
D
These shares represent restricted stock units ("RSUs") that will vest in two equal installments, on the six- and 12-month anniversaries of the grant date, becoming fully vested on the one-year anniversary of the grant date, subject to the reporting person's continued service as of the applicable vesting date.
Includes, as of the transaction date, (i) 25,815 RSUs granted on March 6, 2023 and reported on this Form 4, subject to vesting as set forth in footnote (1); (ii) 13,293 RSUs granted on March 7, 2022, which will vest in full on March 7, 2023; and (iii) 13,293 shares of common stock owned by the reporting person.
These shares are owned by Aisling Capital II LP ("Aisling"). Mr. Elms is Aisling's designee for nomination to the Board. As a Managing Member of Aisling Capital Partners, LLC ("Aisling Partners"), a control person of Aisling, and as a member of the investment committee of Aisling Capital Partners, LP ("Aisling GP"), Mr. Elms may be deemed to be the beneficial owner of shares of common stock owned of record by Aisling. Mr. Elms disclaims beneficial ownership of Aisling's investment in the Company and Aisling Partners' ownership of the Company's options, except to the extent of his pecuniary interest thereon.
The options vest in 12 equal monthly installments, becoming fully vested on the one-year anniversary of the date of grant.
/s/ Steve Elms, by Brian Lenz as Attorney-in-fact
2023-03-08